NMNicola MacDonald

Nicola MacDonald

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicola MacDonald has a total of 194 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Direct to patient testing at cancer diagnosis for precision prevention-2 (DETECT-2): protocol for a 2-arm equivalence UK multi-center randomized controlled trial evaluating uptake of genetic testing

    by Caitlin T Fierheller, Priyanka Deshmukh, Ashwin Kalra, Hamda Mohamed, Wythehi Ambihapathy, Dona Chakraborty, Michail Sideris, Amanda Dibden, Lucy Mitchinson, Bhagyashree Ingle, et al.

  • Open Access

    Ovarian teratoma and the anti-N-methyl-D-aspartate receptor encephalitis paraneoplastic phenomenon: A systematic review and analysis of the literature

    by Dan Conway, Lionel Dufour, Michelle Lockley, Nicola MacDonald, Jeremy Rees, Matthew J. Murray, Sara Stoneham

  • Open Access

    Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London

    by Karim H. El-Shakankery, Joanna Kefas, Kieran Palmer, Andrew Houston, Uma Mukherjee, Kangbo Gao, Weiteen Tan, Shanthini M. Crusz, Michael J. Flynn, Jonathan A. Ledermann, et al.

    Background: Ethnic and socioeconomic disparities in cancer outcomes are exacerbated by clinical trial underrepresentation. This study aims to identify inequalities in ethnicity and socioeconomic features among ovarian cancer clinical trial participants in two London cancer centres. Methods: All ovarian cancer patients treated between 2017 and 2022 were included. Patients participating in clinical trials were classified as the trial population (TP); the remainder were considered the non-trial population (NTP). Data on disease characteristics and sociodemographic features, including ethnicity and Indices of Multiple Deprivation (IMD) deciles, were accessed from electronic patient records. Results: Of the 892 patients, 212 (24%) were enrolled in trials: 87 in Phase II, 103 in Phase III, and 21 in prospective, non-investigational medicinal product trials. The TP were more likely to be of White ethnicity (72.6% vs. 57.5%; p < 0.001), younger (mean age 58 vs. 60; p = 0.003), living in less deprived areas (most deprived tercile: 21.2% vs. 34.0%; p = 0.004), and English-speaking (95.8% vs. 90.9%; p = 0.041). In the multivariate analysis, White ethnicity (p < 0.0001), age (p = 0.003), IMD decile (p = 0.007), and interpreter requirement (p = 0.037) were independent predictors of trial participation. Conclusions: Ethnic and socioeconomic inequalities affect trial participation, potentially worsening health disparities in ovarian cancer patients. Strategies to overcome trial recruitment barriers for underserved groups are needed to improve the equity of care.


  • Open Access

    Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective

    by Farzana Pashankar, Matthew J. Murray, Joanna Gell, Nicola MacDonald, Jonathan Shamash, Deborah F. Billmire, Lindsay Klosterkemper, Thomas Olson, Michelle S. Hirsch, Michelle Lockley, et al.


  • A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold site

    by Veeru Kasivisvanathan, Jamie Lindsay, Sara Rakshani-Moghadam, Ahmed Elhamshary, Konstantinos Kapriniotis, Georgios Kazantzis, Bilal Syed, John Hines, Axel Bex, Daniel Heffernan Ho, et al.

    Background: Two million non-emergency surgeries are being cancelled globally every week due to the COVID-19 pandemic, which will have a major impact on patients and healthcare systems. Methods: During the peak of the pandemic in the United Kingdom, we set up a multicentre cancer network amongst 14 National Health Service institutions, performing urological, thoracic, gynaecological and general surgical urgent and cancer operations at a central COVID-19 cold site. This is a cohort study of 500 consecutive patients undergoing surgery in this network. The primary outcome was 30-day mortality from COVID-19. Secondary outcomes included all-cause mortality and post-operative complications at 30-days. Results: 500 patients underwent surgery with median age 62.5 (IQR 51–71). 65% were male, 60% had a known diagnosis of cancer and 61% of surgeries were considered complex or major. No patient died from COVID-19 at 30-days. 30-day all-cause mortality was 3/500 (1%). 10 (2%) patients were diagnosed with COVID-19, 4 (1%) with confirmed laboratory diagnosis and 6 (1%) with probable COVID-19. 33/500 (7%) of patients developed Clavien-Dindo grade 3 or higher complications, with 1/33 (3%) occurring in a patient with COVID-19. Conclusion: It is safe to continue cancer and urgent surgery during the COVID-19 pandemic with appropriate service reconfiguration.


  • Open Access

    Evaluation of 30-day mortality for 500 patients undergoing non-emergency surgery in a COVID-19 cold site within a multicentre regional surgical network during the COVID-19 pandemic

    by Veeru Kasivisvanathan, Jamie Lindsay, Sara Rakhshani-Moghadam, Ahmed Elhamshary, Konstantinos Kapriniotis, Georgios Kazantzis, Bilal Syed, John Hines, Axel Bex, Daniel Heffernan Ho, et al.

    Background: Two million non-emergency surgeries are being cancelled globally every week due to the COVID-19 pandemic, which will have a major impact on patients and healthcare systems.Objective: To determine whether it is feasible and safe to continue non-emergency surgery in the COVID-19 pandemicDesign, setting and participants: This is a cohort study of 500 consecutive patients undergoing non-emergency surgery in a dedicated COVID-19 cold site following the first case of COVID-19 that was reported in the institution. The study was carried out during the peak of the pandemic in the United Kingdom, which currently has one of the highest number of cases and deaths from COVID-19 globally.We set up a hub-and-spoke surgical network amongst 14 National Health Service institutions during the pandemic. The hub was a cancer centre, which was converted into a COVID-19 cold site, performing urological, thoracic, gynaecological and general surgical operations.Outcomes: The primary outcome was 30-day mortality from COVID-19. Secondary outcomes included all-cause mortality and post-operative complications at 30-days.Results: 500 patients underwent surgery with median age 62.5 (IQR 51-71). 65% were male and 60% had a known diagnosis of cancer. 44% of surgeries were performed with robotic or laparoscopic assistance and 61% were considered complex or major operations.None of the 500 patients undergoing surgery died from COVID-19 at 30-days. 30-day allcause mortality was 3/500 (1%). 10 (2%) patients were diagnosed with COVID-19, 4 (1%) with confirmed laboratory diagnosis and 6 (1%) with probable COVID-19. 33/500 (7%) of patients developed Clavien-Dindo grade 3 or higher complications, with 1/33 (3%) occurring in a patient with COVID-19.Conclusion: It is safe to continue non-emergency surgery during the COVID-19 pandemic with appropriate service reconfiguration.Patient summary: No patients died from COVID-19 when undergoing non-emergency surgery during the pandemic in one of the worst affected world regions.


  • Open Access

    Stepped approach to improving sexual function after gynaecological cancer: the SAFFRON feasibility RCT

    by Sue Gessler, Michael King, Alessandra Lemma, Julie Barber, Louise Jones, Susan Dunning, Val Madden, Stephen Pilling, Rachael Hunter, Peter Fonagy, et al.

    Background: Women affected by gynaecological cancer are often unaware of the sexual consequences of both the cancer and its treatment. Most do not receive appropriate advice or help to recover sexual function, and the effect on their sexuality may be profound, both physically and emotionally. However, several potential therapies can be effective in helping recover some sexual engagement and change self-perception around sex. A major initial challenge is informing and involving patients in an appropriate and sensitive manner, and a further issue is delivering therapies in busy gynaelogical oncology clinics. This study was conceived in response to a National Institute for Health Research (NIHR) Health Technology Assessment (HTA) call asking for proposals to improve sexual functioning in women treated for gynaecological cancer while taking into account associated issues of mood. Existing evidence-based therapies for improving sexual function after cancer treatment were adapted and placed within a ‘stepped care’ model for delivering these in the NHS setting. An assessment and treatment stepping algorithm was developed in parallel, both to assign women to a treatment level at assessment and to follow their progress session by session to advise on changing intervention level. The assessment tool was applied to all participants on the principle that the problem was sexual difficulty, not the cancer of origin. Participants: Women aged > 18 years (with partners at their choice) treated for any gynaecological malignancy with surgery and/or chemotherapy and/or radiation at University College London Hospital or Bristol Gynaecological cancer centres, minimally 3 months post end of treatment, of any sexual orientation, with sexual function difficulties identified by three initial screening questions. Design: A feasibility two-arm, parallel-group randomised controlled pilot trial. Setting: Two NHS gynaecological cancer centres, one in London and one in Bristol. Interventions: A three-level stepped care intervention. Objective: To assess the feasibility of conducting a full-scale investigation of stepped therapy and indicate the potential benefits to patients and to the NHS generally. Primary outcome measures: Recruitment to study, proportion of women stepping up, number of usable data points of all measures and time points over length of trial, and retention of participants to end of trial. Results: Development of the intervention and accompanying algorithm was completed. The study was stopped before the recruitment stage and, hence, no randomisation, recruitment, numbers analysed, outcomes or harms were recorded. Limitations: As the study did not proceed, the intervention and its accompanying algorithm have not been evaluated in practice, and the capacity of the NHS system to deliver it has not been examined. Conclusions: None, as the study was halted. Future work: The intervention could be studied within a clinical setting; however, the experience of the study group points to the need for psychosocial studies in medical settings to establish pragmatic and innovative mechanisms to ensure adequate resource when extending staff clinical skills and time to deliver any new intervention for the duration of the trial. Trial registration: Current Controlled Trials ISRCTN12010952 and ClinicalTrials.gov NCT02458001. Funding: This project was funded by the NIHR HTA programme and will be published in full in Health Technology Assessment; Vol. 23, No. 5. See the NIHR Journals Library website for further project information.

  • Open Access

    Outcome of Patients With Advanced Ovarian Cancer Who Do Not Undergo Debulking Surgery: A Single Institution Retrospective Review

    by Claudia Marchetti, Rebecca Kristeleit, Mary McCormack, Tim Mould, Adeola Olaitan, Martin Widschwendter, Nicola MacDonald, Jonathan A. Ledermann

    (ed from Gynecol Oncol 2017;144:57–60) The cornerstone of ovarian cancer (OC) treatment is debulking surgery to remove all residual disease. Recommended treatment for advanced OC (FIGO [International Federation of Gynecology and Obstetrics] III–IV) is optimal primary debulking surgery followed by platinum-based chemotherapy.